In conclusion, the OSE-mediated inhibition of the RANKL-induced osteoclast differentiation is regulated by the suppression of the expression of c-Fos/NFATc1, a master factor in osteoclast formation, thus highlighting its effective application for the treatment of osteoporosis. Here, FOS is linked to osteoporosis.